Can a cream boost Radiofrequency's Anti-Aging power?

NCT ID NCT07753564

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Aug 07, 2026 · Last updated Aug 07, 2026

Summary

This trial tests whether adding SkinCeuticals A.G.E. Ultra Cream to unipolar radiofrequency treatment improves facial rejuvenation more than radiofrequency alone. Half of each participant's face receives the cream, while the other half gets a standard cream, with the assignment randomized and blinded. Women aged 30-60 with fine lines, wrinkles, and facial sagging are enrolled. The study compares aesthetic improvement between the two sides at 12 weeks.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
unipolar radiofrequency treatment combined with SkinCeuticals A.G.E. Ultra Cream
What this could lead to
If successful, this could point to a more effective non-invasive approach for facial rejuvenation, reducing fine lines and sagging.
What could go wrong
This is a small, early-stage study with subjective outcomes, so results may not be conclusive or widely applicable. Radiofrequency can cause temporary redness or discomfort.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 50 people

The number the study aims to enrol. It can still change while the study runs.

Started

May 2026

Expected to finish

Dec 2027

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

30 to 60 years

Sex

Female participants only

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. Female, aged 30-60 years; 2. Fine lines on both sides of the forehead meet Grade 1-5 according to the Skin Aging Atlas; 3. Crow's feet on both sides meet Grade 2-5 according to the Skin Aging Atlas; 4. Perioral wrinkles on both sides meet Grade 1-7 or nasolabial folds on both sides meet Grade 1-6 according to the Skin Aging Atlas; 5. Lower facial laxity and sagging meet Grade 1-5 according to the Skin Aging Atlas; 6. Subjects with consistent skin condition on both sides of the face who are scheduled to receive unipolar radiofrequency treatment; 7. Able to comply well with the study requirements and maintain a regular lifestyle throughout the study period; 8. Able to read and understand all contents of the informed consent form and voluntarily sign the ICF; 9. Agree not to use any cosmetics, medications, or health supplements that may affect the study results during the trial period. Exclusion Criteria: 1. Allergic constitution or history of severe allergies (e.g., immediate hypersensitivity symptoms, allergic dermatitis); 2. Presence of facial skin diseases (including severe freckles, atopic dermatitis, psoriasis, acute eczema, severe acne, etc.), skin infections (including viral, bacterial, fungal), or skin masses of unknown nature; 3. Presence of large areas of birthmarks, scratch marks, vitiligo, pigmented nevi, keloids, or other skin manifestations on the face that may affect the evaluation; 4. Presence of implantable electronic devices in the body (e.g., pacemaker, implantable cardioverter-defibrillator); 5. Diagnosed with serious clinical conditions such as endocrine diseases, immune system diseases, severe organ failure, or malignant tumors; 6. Diagnosed with severe mental illness or cognitive dysfunction, deemed by the investigator as unable to complete the evaluation or questionnaires involved in the study; 7. Received or planned to receive facial radiofrequency or botulinum toxin treatment within 6 months prior to enrollment or during the study; 8. Received chemotherapy or systemic corticosteroids within 3 months prior to enrollment; 9. Received or planned to receive facial photoelectric treatments (e.g., laser, intense pulsed light), fillers (e.g., sodium hyaluronate, collagen), thread lifts, or other aesthetic procedures within 3 months prior to enrollment or during the study; 10. Received or planned to receive facial mesotherapy or chemical peeling within 1 month prior to enrollment or during the study; 11. Used cosmetics, skincare products, or topical medications with firming or anti-wrinkle claims (e.g., glycolic acid, salicylic acid, mandelic acid, tretinoin, hydroquinone, azelaic acid, adapalene, etc.) on the face within 14 days prior to enrollment; 12. Other conditions that, in the investigator's judgment, render the subject unsuitable for unipolar radiofrequency treatment; 13. Pregnant or breastfeeding women; 14. Participated in other interventional clinical trials within 1 month prior to enrollment; 15. Other circumstances under which the investigator considers the subject should not participate in this clinical trial.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Facial rejuvenation are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Beijing Artemis Medical Beauty Clinic

    RECRUITING

    Beijing, Beijing Municipality, China